Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. on November 22, 2019. The report details the entry into a new material definitive agreement and the termination of a prior agreement regarding the sale of common stock.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed is the authorization of a new equity offering with aggregate gross proceeds of up to $20.0 million.
Material Changes
- New Sales Agreement: On November 25, 2019, the Company entered into an At-The-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated. This agreement allows the sale of up to $20.0 million of common stock.
- Termination of Prior Agreement: The previous At-The-Market Equity Offering Sales Agreement with Stifel, which allowed for the sale of up to $30.0 million, terminated on November 22, 2019, after all shares subject to that agreement were issued and sold.
- Compensation: The Company agreed to pay Stifel a commission of up to 3.0% of the aggregate gross proceeds from shares sold under the new agreement.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond standard securities law disclaimers. The new offering is subject to termination by either party or upon the sale of all authorized shares.
Key Facts for Investor Verification
- Verify the current market price of Cue Biopharma common stock to assess potential dilution from the new $20.0 million offering.
- Confirm the total number of shares sold under the terminated $30.0 million agreement to understand recent capital raising activity.
- Review the Company's cash position in the most recent 10-Q or 10-K to determine the necessity of this new capital raise.
- Check for any subsequent filings indicating the actual volume of shares sold under the new agreement.